Key Highlights

  • Shares trading up 6.77%, adding $2.40 to reach $37.86
  • Completed enrollment of the global Phase 2b MIST trial of AP01 with 398 patients, above the 375-patient target
  • Topline data from the MIST trial expected in the second half of 2027
  • Ended the second quarter with $413.5 million in cash, cash equivalents, and marketable securities
  • Cash runway projected into 2029
  • Two abstracts accepted for presentation at the European Respiratory Society Congress in September

Enrollment Milestone Drives Shares Higher

Avalyn Pharma (NASDAQ:AVLN) shares are surging today, up 6.77% to $37.86, after the clinical-stage biopharmaceutical company reported second-quarter 2026 results that beat consensus loss-per-share estimates and highlighted completed enrollment of its pivotal Phase 2b MIST trial evaluating AP01, an inhaled formulation of pirfenidone, in progressive pulmonary fibrosis. The trial enrolled 398 patients, above its 375-patient target, with topline data expected in the second half of 2027.

Avalyn Pharma is a Boston-based, clinical-stage biopharmaceutical company developing inhaled therapies to treat rare and serious respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. Its proprietary drug-device approach delivers optimized inhaled formulations of established antifibrotic medicines directly to lung tissue, aiming to enhance local efficacy while reducing systemic side effects. The pipeline is led by AP01 and AP02, inhaled formulations of pirfenidone and nintedanib respectively, along with AP03, a fixed-dose combination of both agents.

Strong Balance Sheet Supports Continued Investment

Investors are also encouraged by the company's strong balance sheet, with $413.5 million in cash following its May 2026 IPO providing a runway into 2029, alongside newly accepted data presentations at the upcoming European Respiratory Society Congress in Barcelona this September. Research and Development expenses rose to $24.7 million in the second quarter, up from $17.9 million a year earlier, primarily driven by the ongoing AP01 and AP02 clinical trials, while net loss widened to $28.9 million from $20.2 million in the prior-year period.

"Completing global enrollment in MIST marks a significant milestone for Avalyn, and the degree of over-enrollment in this study is a testament to the high level of interest from investigators and patients," said Lyn Baranowski, Chief Executive Officer of Avalyn Pharma. The company's AP02 program, evaluating inhaled nintedanib in idiopathic pulmonary fibrosis, remains on track with enrollment in its Phase 2 AURA trial, while a Phase 1 study of combination candidate AP03 remains on track to initiate by the end of 2026.

Broader Sector Backdrop

The move comes amid broader biotech sector strength, with analysts maintaining a consensus 'Buy' rating and average price target of $59, well above current trading levels, as investors weigh the significance of completed late-stage enrollment against the company's continued elevated cash burn.

Conclusion

Avalyn Pharma's 6.77% gain reflects investor enthusiasm for the completed enrollment of its pivotal Phase 2b MIST trial, a key milestone on the path toward a potential 2027 data readout, combined with a well-funded balance sheet supporting operations into 2029. With two abstracts set for presentation at the upcoming European Respiratory Society Congress and a consensus analyst price target well above current levels, the stock's next moves will likely hinge on continued execution across its inhaled respiratory disease pipeline.